{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:41:47Z","timestamp":1780411307852,"version":"3.54.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0121822","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T02:32:47Z","timestamp":1427596367000},"page":"e0121822","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas"],"prefix":"10.1371","volume":"10","author":[{"given":"Giuseppe","family":"Gritti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Boschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Delaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Algarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Trezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gianatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"J Delabie","year":"2011","journal-title":"Blood"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"DD Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"KJ Savage","year":"2008","journal-title":"Blood"},{"issue":"25","key":"ref4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"J Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1023\/A:1008392528248","article-title":"CHOP versus MACOP-B in aggressive lymphoma\u2014a Nordic Lymphoma Group randomised trial","volume":"10","author":"M Jerkeman","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"ref6","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"C Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"HC Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"A Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"ref9","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"N Schmitz","year":"2010","journal-title":"Blood"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"A Gallamini","year":"2007","journal-title":"Blood"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"MP Escalon","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"ref12","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"C Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"AI Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"J Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"25","key":"ref15","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma","volume":"31","author":"SM Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"P Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"J Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"P Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"M Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"S Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"25","key":"ref21","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"F d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref22","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","author":"P Corradini","year":"2014","journal-title":"Leukemia"},{"key":"ref23","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","article-title":"MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma","volume":"102","author":"P Klimo","year":"1985","journal-title":"Ann Intern Med"},{"issue":"18","key":"ref25","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"R Bassan","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"BD Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"A Gallamini","year":"2004","journal-title":"Blood"},{"issue":"13","key":"ref29","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"E Jantunen","year":"2013","journal-title":"Blood"},{"key":"ref30","unstructured":"Non-Hodgkin's Lymphomas. NCCN Clinial Practice Guidelines in Oncology 2013;Version 2."},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"CE Dearden","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"ref32","first-page":"515","article-title":"Therapies for Peripheral T-Cell Lymphomas","volume":"2011","author":"KJ Savage","year":"2011","journal-title":"ASH Education Program Book"},{"issue":"21","key":"ref33","first-page":"550","article-title":"Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses\u2014First Interim Analysis of the GITIL\/FIL HD0607 Clinical Trial","volume":"120","author":"A Gallamini","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: a study from the GOELAMS group","volume":"22","author":"X Cahu","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"ref35","first-page":"2721","article-title":"The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP","volume":"120","author":"C Pellegrini","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"C Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11864-013-0232-x","article-title":"Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?","volume":"14","author":"MA Lunning","year":"2013","journal-title":"Curr Treat Options Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0121822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:03:55Z","timestamp":1589015035000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0121822"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0121822","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}